Targeted drug duo shows promise in halting tough pancreatic cancer
NCT ID NCT05068752
Summary
This study tested a combination of two oral drugs, vemurafenib and sorafenib, in 10 patients with advanced pancreatic cancer that had a specific genetic change (KRAS mutation) and had stopped responding to standard chemotherapy. The main goal was to see if the drug combo could control the cancer for at least 16 weeks. Researchers also tracked side effects, survival, and changes in blood markers to understand how the treatment worked.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
Conditions
Explore the condition pages connected to this study.